Breast cancer (invasive) · line 2 · Olaparib monotherapy (BRCA-mutant HER2- breast: metastatic OR adjuvant high-risk early)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	standard
Linked regimen	`REG-OLAPARIB-BREAST`

ID	`IND-BREAST-TNBC-2L-BRCA-TALAZOPARIB`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-BREAST`
Sources	`SRC-EMBRACA-LITTON-2018` `SRC-ESMO-BREAST-METASTATIC-2024` `SRC-NCCN-BREAST-2025`

Notes

ESCAT IA. EMBRACA established talazoparib (1 mg PO daily) for germline BRCA1/2-mutant HER2- metastatic breast (≤3 prior cytotoxic regimens). Comparable efficacy to olaparib (no head-to-head trial), different AE profile: more haematologic (anaemia G3+ ~39%), less GI than olaparib. Patient preference and AE-profile drive the olaparib-vs-talazoparib choice. KNOWN GAP: dedicated REG-TALAZOPARIB-BREAST regimen entry not yet authored — current placeholder points to REG-OLAPARIB-BREAST. Engine trace must surface that talazoparib dosing differs (1 mg PO daily monotherapy continuous; reduce to 0.75 mg if anaemia, then 0.5 mg). Follow-up authoring task. UA access: talazoparib not reimbursed.

Used By

Algorithms

ALGO-BREAST-TNBC-2L - ALGO-BREAST-TNBC-2L